Could a cholesterol drug protect heavy Drinkers' livers?
NCT ID NCT04781322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether alirocumab, a drug approved for high cholesterol, is safe for heavy drinkers and might reduce liver inflammation. One hundred healthy adults who drink heavily will receive either alirocumab or a placebo injection over 8 weeks. Researchers will monitor side effects, liver health, and drinking behavior.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alirocumab (a drug that lowers cholesterol by blocking a protein called PCSK9)
What this could lead to
If it works, this could point toward a treatment to reduce liver inflammation and damage in heavy drinkers.
What could go wrong
This is an early Phase 1 safety study with only 100 people, so it may not show clear benefits. The drug is not proven for alcohol-related liver issues and may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL ASSOCIATED LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••